Show simple item record

dc.contributor.authorCosta, S.
dc.contributor.authorIravani, Mahmoud M.
dc.contributor.authorPearce, R. K. B.
dc.contributor.authorJenner, P.
dc.date.accessioned2013-06-18T12:15:42Z
dc.date.available2013-06-18T12:15:42Z
dc.date.issued2001-01-19
dc.identifier.citationCosta , S , Iravani , M M , Pearce , R K B & Jenner , P 2001 , ' Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets ' , European Journal of Pharmacology , vol. 412 , no. 1 , pp. 45-50 .
dc.identifier.issn0014-2999
dc.identifier.otherORCID: /0000-0002-4905-9682/work/32997602
dc.identifier.urihttp://hdl.handle.net/2299/10827
dc.description.abstractGlial cell line-derived neurotrophic factor (GDNF) has previously reduced motor deficits and preserved nigral dopamine neurones in rhesus monkeys with a unilateral MPTP-induced lesion of substantia nigra. We now report on the ability of GDNF to reverse motor deficits induced by parenteral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets resulting in bilateral degeneration of the nigrostriatal pathway. Prior to GDNF administration, all MPTP-treated animals showed akinesia or bradykinesia, rigidity, postural instability and tremor. Intraventricular injection of GDNF (10, 100 or 500 mug) at 9 and 13 weeks post MPTP treatment resulted in a concentration dependent improvement in locomotor activity and motor disability which became significant after administration of 100 and 500 mug of GDNF. The most prominent improvements were in alertness, checking movements, and posture. It is concluded that intraventricular GDNF administration improves bilateral Parkinsonian motor disability following MPTP treatment and this may reflect an action of GDNF on remaining nigral dopaminergic neurones. (C) 2001 Elsevier Science B.V. All rights reserved.en
dc.format.extent6
dc.language.isoeng
dc.relation.ispartofEuropean Journal of Pharmacology
dc.subjectdopamine
dc.subjectGDNF (glial cell line-derived neurotrophic factor)
dc.subjectParkinson's disease
dc.subjectMPTP primate
dc.subjectmotor activity
dc.subjectNIGROSTRIATAL DOPAMINERGIC SYSTEM
dc.subjectPARKINSONIAN MONKEYS
dc.subjectGDNF
dc.subjectNEURONS
dc.subjectBRAIN
dc.subjectRECOVERY
dc.subjectDISEASE
dc.subjectMODEL
dc.subjectMICE
dc.titleGlial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosetsen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionCentre for Research in Mechanisms of Disease and Drug Discovery
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.description.statusPeer reviewed
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record